insiderwall
Menu
SuperinvestorInsider
Xencor Inc. XNCR

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics. Powered by its proprietary XmAb protein engineering platform, Xencor designs drug candidates optimized for enhanced efficacy and safety profiles to treat

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees250
TickerXNCR

Statistics

Market Cap$947.3M
Revenue (TTM)$125.6M
Net Income-$91.9M
Net Margin-73.2%
EPS$-1.24
P/E-10.00
P/S9.04
P/B1.34
EV/EBITDA-3.03
ROE-29.8%
Dividend Yield
Price$12.79

Data: Twelve Data · Revenue = mcap / P/S